CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-01 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 260,550 | ||
| 2024-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 3,250 |
| 2024-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,068 | $18.22 | $56K | 182 |
| 2024-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −182 | $18.72 | $3K | 0 |
| 2024-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 239,370 | ||
| 2024-03-25 | Kintz Samuel PRESIDENT AND CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-03-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −7,329 | $17.17 | $126K | 4,671 |
| 2024-03-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −4,671 | $18.16 | $85K | 0 |
| 2024-03-25 | Kintz Samuel PRESIDENT AND CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 260,550 | ||
| 2024-03-20 | Ballal Rahul D. Director | Option exercise 10b5-1 | +13,278 | $5.52 | $73K | 35,619 |
| 2024-03-20 | Ballal Rahul D. Director | Sale 10b5-1 | −13,278 | $19.16 | $254K | 22,341 |
| 2024-03-20 | Ballal Rahul D. Director | Option exercise · Stock Option (right to buy) 10b5-1 | −13,278 | 19,571 | ||
| 2024-03-19 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $14.50 | $18K | 143,470 |
| 2024-03-06 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −4,875 | $15.64 | $76K | 7,472 |
| 2024-02-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-02-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −10,195 | $16.30 | $166K | 1,805 |
| 2024-02-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −1,805 | $17.09 | $31K | 0 |
| 2024-02-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 272,550 | ||
| 2024-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 3,250 |
| 2024-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $16.97 | $55K | 0 |
Page 24 of 37 · 724 trades